| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.2 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.2 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |